Radformation

Healthcare technology for radiation therapy planning

New York City, New York, United States

About Radformation

Radformation provides software tools that improve the treatment planning process for radiation therapy in healthcare. Their products, which are FDA-cleared, include ClearCheck for automating plan checks, ClearCalc for independent dose validation, EZFluence for creating 3D treatment plans, AutoContour for AI-driven contouring, ChartCheck for monitoring patient data in real-time, and QuickCode for billing quality assurance. These tools are designed to integrate smoothly into existing workflows at clinics and healthcare facilities. Radformation stands out from competitors by focusing on automation, which helps clinics save time and resources while maintaining high standards of patient care. The company's goal is to enhance the efficiency and quality of radiation therapy treatment planning.

New York City, New YorkHeadquarters
2016Year Founded
$8.9MTotal Funding
EARLY_VCCompany Stage
AI & Machine Learning, HealthcareIndustries
51-200Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Parental Leave
Remote Work Options

Risks

Emerging AI-driven startups may challenge Radformation's market position with competitive solutions.
Rapid technological advancements require continuous R&D investment to maintain competitiveness.
Economic instability in key markets could impact Radformation's sales and expansion plans.

Differentiation

Radformation offers FDA-cleared software tools for radiation therapy workflow automation.
Their AI-driven solutions enhance treatment planning efficiency and accuracy in cancer care.
Radformation's products integrate seamlessly into existing clinical workflows, saving time and resources.

Upsides

Acquisition of Limbus AI enhances Radformation's AI capabilities in radiation therapy.
Regulatory clearances in multiple countries indicate global acceptance and growth potential.
Partnership with Icon Group expands market reach and improves cancer care workflows.

Funding

Total raised$8.91 M
Latest valuation$34.50 M
StageEARLY_VC
EARLY VC
4/30/2023
$7
$34.50 M
$2
$8.00 M